It’s well-known that clinical trials are one of the most expensive parts of the drug development process. Addressable bottlenecks include improving access to knowledge for protocol design such as appropriate biomarkers, clinical outcomes, eligibility criteria, assessment schedules, and more.
June 30, 2022 | 8:30-9:30PM GMT+
